NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing
Status:
Not yet recruiting
Trial end date:
2030-02-01
Target enrollment:
Participant gender:
Summary
Prospective, non-randomized, open-label, single-arm phase II trial to investigate the
feasibility and efficacy of combining chemotherapy with tiragolumab and atezolizumab as
neoadjuvant and adjuvant treatment for surgical NSCLC patients.
Phase:
Phase 2
Details
Lead Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest